The China Alzheimer’s disease diagnostics market was estimated at USD 319.6 million in 2024 and is projected to reach USD 617.8 million by 2030, growing at a CAGR of 11.7% from 2025 to 2030. The increasing prevalence of Alzheimer’s disease (AD), growing adoption of personalized products, growing use of biomarkers in disease diagnostics, and growing technological advancements in medical imaging are expected to drive the market growth.
Increasing government investments and R&D studies are further propelling growth. One major growth driver for China’s Alzheimer’s disease diagnostics market is its rapidly aging population. With over 280 million people aged 60 and above, the country faces a surge in age-related diseases, including Alzheimer’s. This demographic shift is increasing demand for early detection and intervention tools. In response, the Chinese government is prioritizing dementia screening under its national health agenda. Public hospitals are expanding diagnostic infrastructure, and local biotech firms are accelerating R&D in biomarker testing. Additionally, collaborations with global firms are boosting access to advanced imaging and blood-based diagnostics. This environment fosters strong market expansion for Alzheimer’s diagnostics in China.
In June 2024, the launch of LEQEMBI in China by Eisai Co., Ltd. and Biogen Inc. marked a significant driving factor in the market. Following its approval in January 2024 for treating mild cognitive impairment (MCI) and mild Alzheimer's dementia, China became the third country to introduce LEQEMBI, after the U.S. and Japan. With an estimated 17 million individuals in China affected by early-stage Alzheimer's in 2024, the number is expected to grow with the aging population. Eisai is actively building an early AD diagnosis and treatment pathway. This approach combines online and offline services, including collaboration with commercial health insurance companies, private health checkups, and nursing homes.
In addition, Eisai fosters early detection through disease awareness campaigns, pre-screening opportunities, and referrals to specialized hospitals or "Yin Fa Tong," an online platform developed with JD Health. Eisai’s efforts, including using blood biomarkers for definitive diagnosis, are poised to significantly impact the market growth and development, supporting early detection and treatment within a comprehensive dementia care ecosystem.
China's aging population has expanded rapidly since the 2010 census, leading to a significant rise in the incidence, morbidity, and mortality of age-related diseases, particularly Alzheimer's disease (AD). The increasing prevalence of AD poses substantial medical and social challenges, severely impacting both urban and rural communities. Recent data reveal that 15.07 million people aged 60 and over in China suffer from dementia, with 9.83 million affected by AD, 3.92 million by vascular dementia, and 1.32 million by other forms of dementia.
Furthermore, 15.5% of those over 60 have mild cognitive impairment (MCI), affecting approximately 38.77 million individuals. The economic burden is immense, with AD treatment costs soaring from USD 167.74 billion in 2015 to a projected USD 1.8 trillion by 2050. Despite this, China's diagnosis and treatment rates for AD remain alarmingly low, compounded by a shortage of medical specialists and limited public awareness. Addressing these issues through government-led initiatives to enhance AD prevention and treatment is urgently needed to mitigate the growing crisis.
Initiatives like the 'Guangci Home Ruijian Cognitive Science Popularization Volunteer Service Team' at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, represent key driving factors in the market. This team conducts disease screening and educational outreach in communities and homes, emphasizing 'Early prevention, detection, diagnosis, and treatment.' Supported by the Shanghai Voluntary Service Public Welfare Foundation, such efforts highlight the growing focus on early intervention.
Similarly, the Beijing Senior Care Centre’s decade-long program uses art therapy to meet the deeper needs of seniors with dementia, enhancing their well-being. In addition, the Shanghai Jian’ai Charity Development Center’s ‘Anti-dementia Manual Assemblage’ activities foster social interaction among older adults through creative exercises. The Shanghai Brain Health Alliance, established by 141 institutions under the guidance of the Shanghai Medical Society General Medical Section and in line with WHO's Global Action Plan on Dementia, aims to enhance the diagnosis and treatment of cognitive impairment. By integrating prevention, screening, diagnosis, treatment, and long-term management into a cohesive system, these initiatives are set to significantly boost the detection and treatment rates of Alzheimer's disease, thereby driving advancements in the market in China.
Currently, there are no standardized cutoff values for Alzheimer's disease (AD) biomarkers in the Chinese population, which presents a challenge for consistent diagnosis. However, as part of the Alzheimer’s Association Quality Control (QC) program for cerebrospinal fluid (CSF) biomarkers, researchers have made significant progress by establishing diagnostic cutoff values for core CSF biomarkers in a Chinese cohort. Using methods recommended by the QC program, they developed an optimal diagnostic model that combines these biomarkers. This study represents a critical step toward defining uniform cutoff values tailored to the Chinese population, facilitating the integration of CSF biomarkers into clinical practice. This advancement is poised to enhance the accuracy and reliability of AD diagnostics in China, thereby driving growth in the country's Alzheimer’s disease diagnostics market.
This product will be delivered within 1-3 business days.
Increasing government investments and R&D studies are further propelling growth. One major growth driver for China’s Alzheimer’s disease diagnostics market is its rapidly aging population. With over 280 million people aged 60 and above, the country faces a surge in age-related diseases, including Alzheimer’s. This demographic shift is increasing demand for early detection and intervention tools. In response, the Chinese government is prioritizing dementia screening under its national health agenda. Public hospitals are expanding diagnostic infrastructure, and local biotech firms are accelerating R&D in biomarker testing. Additionally, collaborations with global firms are boosting access to advanced imaging and blood-based diagnostics. This environment fosters strong market expansion for Alzheimer’s diagnostics in China.
In June 2024, the launch of LEQEMBI in China by Eisai Co., Ltd. and Biogen Inc. marked a significant driving factor in the market. Following its approval in January 2024 for treating mild cognitive impairment (MCI) and mild Alzheimer's dementia, China became the third country to introduce LEQEMBI, after the U.S. and Japan. With an estimated 17 million individuals in China affected by early-stage Alzheimer's in 2024, the number is expected to grow with the aging population. Eisai is actively building an early AD diagnosis and treatment pathway. This approach combines online and offline services, including collaboration with commercial health insurance companies, private health checkups, and nursing homes.
In addition, Eisai fosters early detection through disease awareness campaigns, pre-screening opportunities, and referrals to specialized hospitals or "Yin Fa Tong," an online platform developed with JD Health. Eisai’s efforts, including using blood biomarkers for definitive diagnosis, are poised to significantly impact the market growth and development, supporting early detection and treatment within a comprehensive dementia care ecosystem.
China's aging population has expanded rapidly since the 2010 census, leading to a significant rise in the incidence, morbidity, and mortality of age-related diseases, particularly Alzheimer's disease (AD). The increasing prevalence of AD poses substantial medical and social challenges, severely impacting both urban and rural communities. Recent data reveal that 15.07 million people aged 60 and over in China suffer from dementia, with 9.83 million affected by AD, 3.92 million by vascular dementia, and 1.32 million by other forms of dementia.
Furthermore, 15.5% of those over 60 have mild cognitive impairment (MCI), affecting approximately 38.77 million individuals. The economic burden is immense, with AD treatment costs soaring from USD 167.74 billion in 2015 to a projected USD 1.8 trillion by 2050. Despite this, China's diagnosis and treatment rates for AD remain alarmingly low, compounded by a shortage of medical specialists and limited public awareness. Addressing these issues through government-led initiatives to enhance AD prevention and treatment is urgently needed to mitigate the growing crisis.
Initiatives like the 'Guangci Home Ruijian Cognitive Science Popularization Volunteer Service Team' at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, represent key driving factors in the market. This team conducts disease screening and educational outreach in communities and homes, emphasizing 'Early prevention, detection, diagnosis, and treatment.' Supported by the Shanghai Voluntary Service Public Welfare Foundation, such efforts highlight the growing focus on early intervention.
Similarly, the Beijing Senior Care Centre’s decade-long program uses art therapy to meet the deeper needs of seniors with dementia, enhancing their well-being. In addition, the Shanghai Jian’ai Charity Development Center’s ‘Anti-dementia Manual Assemblage’ activities foster social interaction among older adults through creative exercises. The Shanghai Brain Health Alliance, established by 141 institutions under the guidance of the Shanghai Medical Society General Medical Section and in line with WHO's Global Action Plan on Dementia, aims to enhance the diagnosis and treatment of cognitive impairment. By integrating prevention, screening, diagnosis, treatment, and long-term management into a cohesive system, these initiatives are set to significantly boost the detection and treatment rates of Alzheimer's disease, thereby driving advancements in the market in China.
Currently, there are no standardized cutoff values for Alzheimer's disease (AD) biomarkers in the Chinese population, which presents a challenge for consistent diagnosis. However, as part of the Alzheimer’s Association Quality Control (QC) program for cerebrospinal fluid (CSF) biomarkers, researchers have made significant progress by establishing diagnostic cutoff values for core CSF biomarkers in a Chinese cohort. Using methods recommended by the QC program, they developed an optimal diagnostic model that combines these biomarkers. This study represents a critical step toward defining uniform cutoff values tailored to the Chinese population, facilitating the integration of CSF biomarkers into clinical practice. This advancement is poised to enhance the accuracy and reliability of AD diagnostics in China, thereby driving growth in the country's Alzheimer’s disease diagnostics market.
China Alzheimer's Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, the analyst has segmented the China Alzheimer’s disease diagnostics market report on the basis of diagnostic technique, type and end-use:Diagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030)
- Biomarkers
- CSF Biomarkers
- Blood-based Biomarkers
- Imaging Techniques
- Genetic Testing
- Cognitive Assessment Tests
Type Outlook (Revenue, USD Million, 2018 - 2030)
- Triage
- Diagnosis
- Screening
End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. China Alzheimer’s Disease Diagnostics Market Variables, Trends & Scope
Chapter 4. China Alzheimer’s Disease Diagnostics Market: Diagnostic Technique Estimates & Trend Analysis
Chapter 5. China Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
Chapter 6. China Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- FujireBio
- ALZpath
- Quanterix
- Roche Diagnostics
- Life Molecular Imaging
- Quest Diagnostics.
- Labcorp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 319.6 Million |
| Forecasted Market Value ( USD | $ 617.8 Million |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | China |
| No. of Companies Mentioned | 7 |
